Ufp Technologies SEC Filings

UFP Technologies CEO Jeffrey R. Bailly reported a Form 4 transaction showing a tax-withholding disposition of company stock rather than an open-market trade. On stock units that vested on March 2, 2026, 9,422 shares of common stock at $204.30 per share were withheld to cover tax liabilities. After this withholding, he directly owns 170,163 shares of UFP Technologies common stock. A footnote adds that he also has an indirect interest in 28,706 shares held by a trust, for which he disclaims beneficial ownership except to the extent of any pecuniary interest.

UFP Technologies, Inc. files its annual report describing a fast-growing contract development and manufacturing business focused on single-use and single-patient medical devices for leading global OEMs. Its products support minimally invasive surgery, infection prevention, wound care, orthopedics, wearables and biopharma applications.

The company operates a global footprint of ISO 13485-certified and FDA-registered plants, including major facilities in the U.S., Dominican Republic, Mexico, Puerto Rico, Ireland and Costa Rica. Two customers, Intuitive Surgical SARL and Stryker, accounted for approximately 24.3% and 21.5% of 2025 net sales, while the top ten customers represented 68.8%, underscoring significant customer concentration risk.

Market capitalization held by non‑affiliates was about $1,814,993,392 as of June 30, 2025, based on a $244.16 share price, with 7,713,300 shares outstanding in early 2026. The workforce expanded to 4,846 full‑time employees and 503 temporary workers, reflecting continued scaling.

Key risks highlighted include inflationary cost pressures, supply-chain and raw material dependence, geopolitical and climate-related disruptions, cybersecurity threats, heavy reliance on a few customers, regulatory and ESG developments, and challenges integrating acquisitions. The company discloses a February 2026 cyber incident that disrupted some IT systems but reports operations and financial condition remain materially intact so far.

UFP Technologies has provided an updated investor presentation outlining its MedTech-focused contract manufacturing business, strategy, and financial targets. The company reports annual revenue of $603 million, with about 92% coming from medical technology customers and a market capitalization of roughly $1.7 billion as of February 26, 2026.

The presentation highlights exposure to a $550 billion global medical device market growing around 6%, and a $101 billion medical device CDMO market growing near 10%. Management targets 12–18% revenue growth, 28–31% gross margin, and 17–20% adjusted operating margin over three to five years. Historical gross margins increased from 24.9% in 2020 to 29.1% in 2024, while adjusted operating margin rose from 10.3% to 18.3% over the same period, before measuring 17.1% in 2025.

The materials also show a long-term stock price increase of 9,340% over 20 years through February 12, 2026, and describe a two-pronged growth strategy combining organic expansion in high-growth MedTech niches with acquisitions designed to be accretive within the first year.

UFP Technologies, Inc. has amended its long-term Manufacturing Supply Agreement with strategic medical customer Intuitive Surgical SARL. Through a wholly owned subsidiary, the company entered into Amendment No. 27, effective January 1, 2026.

The amendment extends the agreement’s term by two years through December 31, 2029, materially increases annual minimum volumes for the largest program in 2028 and 2029, adds an additional program, and introduces volume-based pricing tied to minimum purchase thresholds and cost-sharing provisions.

UFP Technologies, Inc. reported a material cybersecurity incident affecting many of its information technology systems, including functions such as billing and label making for customer deliveries. The company detected suspicious activity on or about February 14, 2026 and engaged external cybersecurity advisors to investigate.

UFP Technologies isolated affected systems, removed the third party from its IT environment, and restored access to impacted information in all material respects. Certain company or company-related data appears to have been stolen or destroyed, and some files were exfiltrated. The company is still determining whether sensitive or personal information was involved.

Operations have continued in all material respects, supported by contingency plans and data backups. The company expects a significant portion of direct response costs to be reimbursed through insurance and states that, as of this report, the incident has not had a material impact on its financial systems, operations, or financial condition, nor is it believed reasonably likely to do so.

UFP Technologies reported record 2025 results, with net income of $68.3 million, up 15.8% from 2024, and net sales of $602.8 million, a 19.5% increase. GAAP diluted EPS rose to $8.75, while adjusted EPS reached $9.76.

Growth was driven by a 23.2% increase in medical-market sales to $555.3 million, while non-medical sales fell 11.5% to $47.5 million. Organic sales growth for 2025 was 1.5%, reflecting a significant contribution from acquisitions.

Gross margin slipped to 28.3% from 29.1%, pressured by about $6.3 million of labor-related inefficiencies at the AJR facility. Even so, operating income climbed 14.1% to $92.3 million, adjusted EBITDA increased to $121.1 million, and long-term debt declined from $176.9 million to $123.0 million, strengthening the balance sheet.

UFP Technologies outlined compensation changes tied to its leadership transition and 2026 incentive programs. The board confirmed an Employment Offer Letter for Mitchell C. Rock, who becomes Chief Executive Officer on June 4, 2026, with a $700,000 base salary, an annual bonus opportunity up to 100% of salary, and long‑term incentive awards in restricted stock units.

Rock will receive a one‑time $650,000 RSU grant and, beginning in 2027, will be eligible for annual LTI awards targeted at up to $3,000,000 in RSUs. His severance agreement provides 18 months of base salary and COBRA reimbursement if terminated without cause or for good reason, and enhanced cash and full equity vesting upon a qualifying change of control.

The Compensation Committee also raised 2026 base salaries for senior executives and granted stock unit and performance share awards with multi‑year vesting and performance conditions. Outgoing CEO R. Jeffrey Bailly received 19,061 stock units, described as $5.1 million in value, vesting in 2027, along with a 2026 performance bonus plan and continued equity protections under his existing agreement.

UFP Technologies Vice President Jason Holt reported stock-based awards that increase his direct ownership. On February 10, 2026, he acquired 657 shares of common stock at $0 upon achievement of performance targets tied to restricted stock units originally granted on February 11, 2025. He also received 1,121 time-based stock unit awards on the same date at $0, all under the company’s 2003 Incentive Plan.

These units are to be settled solely in common shares and vest in equal one-third installments on March 1 dates from 2026 through 2029, contingent on continued employment. Following these awards, Holt directly beneficially owns 9,456 shares of UFP Technologies common stock.

UFP Technologies Senior Vice President Christopher P. Litterio reported stock-based awards tied to company performance and service. On February 10, 2026, he acquired 821 shares of common stock at $0, reflecting performance-based restricted stock units granted on February 11, 2025 under the 2003 Incentive Plan.

He also acquired 1,215 shares at $0 from time-based stock unit awards granted on February 10, 2026. After these awards, he directly held 12,792 shares of common stock. The performance units vest in thirds each March 1 from 2026 through 2028, and the time-based units vest in thirds each March 1 from 2027 through 2029, contingent on continued employment.